icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
Low Rates of De Novo or Recurrent Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct-Acting Antivirals (DAAs): A Single-Center Experience
  AASLD: The incidence of hepatocellular carcinoma is not increased after DAA therapy - (11/13/17)
AASLD: Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality and Hepatocellular Carcinoma - significantly lower mortality, HCC 60% to 84% - (10/24/17)
AASLD: Eradication of HCV induced by DAAs is associated with a 71% reduction in HCC risk - (10/24/17)
AASLD: Impact of a Structured Hepatocellular Carcinoma Surveillance Program in Patients with Cirrhosis: Frequency, Evaluation and Subsequent Clinical Outcomes of Patients with Abnormal Imaging Findings - (11/13/17)
Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
E. Degasperi1, R. D'Ambrosio1, A. Sangiovanni1, A. Aghemo2,3, R. Soffredini1, S. De Nicola4, G. Lunghi5, M. Colombo2,3 and P. Lampertico1
1Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 2Humanitas University Department of Biomedical Sciences, Rozzano-Milan, Italy; 3Humanitas Clinical and Research Center, Rozzano-Milan, Italy; 4Hepatology and Gastroenterology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; 5Microbiology and Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy